Keith Katkin Sells 15,481 Shares of Emergent Biosolutions (NYSE:EBS) Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Keith Katkin sold 15,481 shares of Emergent Biosolutions stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $8.28, for a total value of $128,182.68. Following the completion of the sale, the director owned 96,294 shares of the company’s stock, valued at approximately $797,314.32. The trade was a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Shares of NYSE:EBS opened at $9.06 on Wednesday. The stock has a market capitalization of $467.70 million, a P/E ratio of -32.35 and a beta of 2.33. Emergent Biosolutions Inc. has a 1-year low of $4.71 and a 1-year high of $14.06. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. The business has a 50-day moving average price of $8.50 and a two-hundred day moving average price of $10.30.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Analyst Upgrades and Downgrades

A number of research firms have commented on EBS. HC Wainwright lowered their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 9th. Weiss Ratings downgraded Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, April 27th. Finally, Wall Street Zen lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $12.00.

Institutional Trading of Emergent Biosolutions

A number of hedge funds have recently modified their holdings of the company. Legal & General Group Plc bought a new position in Emergent Biosolutions during the 2nd quarter worth approximately $31,000. Torren Management LLC bought a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $37,000. CANADA LIFE ASSURANCE Co bought a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $45,000. Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions in the second quarter worth $53,000. Finally, Farther Finance Advisors LLC raised its holdings in Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 4,827 shares during the period. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Q1 results beat consensus — Emergent reported $0.21 EPS vs. a consensus loss and revenue of $156.1M vs. ~$145M expected, which provides fundamental support for the stock. MarketBeat EBS coverage
• Neutral Sentiment: Directors reported the sales were executed under pre-arranged Rule 10b5-1 plans — a disclosure that typically reduces the negative signal from insider selling because trades were planned in advance. InsiderTrades alert
• Negative Sentiment: Director Kathryn C. Zoon sold 17,202 shares (~17.7% reduction of her holding) at about $8.40 per share — a sizable individual sale that could be perceived negatively by some investors. Zoon sale article
• Negative Sentiment: Director Keith Katkin sold 15,481 shares (≈13.9% reduction) at roughly $8.28 per share — another material director sale disclosed this week. Katkin sale article
• Negative Sentiment: Director Donald W. Degolyer sold 15,481 shares (≈10.7% reduction) at about $8.40 per share — adds to the cluster of director selling. Degolyer sale article
• Negative Sentiment: Director Sujata Tyagi Dayal sold 13,761 shares (≈12.0% reduction) at an average ~$8.40; filing notes the director still holds a six-figure stake and the sale was under a 10b5-1 plan. Dayal sale article

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.